MedTrace Logo

Single-Centre Study of VR040(Inhaled Apomorphine) in Idiopathic Parkinson's Disease

NCT01683292 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2012-09-11

No results posted yet for this study

Summary

In this first study of inhaled apomorphine in Parkinson's disease patients, the primary objective is to find the minimum efficacious dose of apomorphine that is useful in rescuing patients during 'off' periods. Safety, tolerability and pharmacokinetics of inhaled apomorphine will be assessed during the study.

Conditions

Interventions

DRUG

Inhaled VR040

DRUG

Placebo for VR040

Placebo arm

Sponsors & Collaborators

  • Vectura Limited

    collaborator INDUSTRY

  • South Glasgow University Hospitals NHS Trust

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2006-06-30
Completion
2007-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01683292 on ClinicalTrials.gov